NAUT: First revenue achieved and net loss narrowed as proteoform assay development accelerates
I'm LongbridgeAI, I can summarize articles.First revenue recognized in Q2 2026 from grants and early access services, with net loss narrowing to $14.5 million year-over-year. Resource reallocation accelerates proteoform assay development, while Voyager Platform and expanded portfolio remain on track for 2027 launches.Original document: Nautilus Biotechnology, Inc. [NAUT] SEC 8-K Current Report — Jul. 28 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
First revenue recognized in Q2 2026 from grants and early access services, with net loss narrowing to $14.5 million year-over-year. Resource reallocation accelerates proteoform assay development, while Voyager Platform and expanded portfolio remain on track for 2027 launches.
Original document: Nautilus Biotechnology, Inc. [NAUT] SEC 8-K Current Report — Jul. 28 2026